Use of tricyclic derivatives of 1,4-dihydro-1,4-dioxo-1H-naphthalene, novel compounds obtained and their application in theraphy
申请人:Laboratoire Innothera
公开号:US06262095B1
公开(公告)日:2001-07-17
The invention concerns the therapeutic use of tricyclic salts and their pharmaceutically acceptable salts having the general formula:
in which:
A is either a sulfur atom, an oxygen atom, or an R3N radical where R3 is a hydrogen atom, a C1-C5 alkyl radical, or a substituted or unsubstituted aromatic ring, or a substituted or unsubstituted heteroaromatic ring.
R1 is either a C1-C5 alkyl radical,
or an R4NH radical where R4 is a hydrogen atom, a C1-C5 alkyl radical, or a substituted or unsubstituted aromatic ring, or a substituted or unsubstituted heteroaromatic ring,
or an aromatic ring that may or may not be substituted by one or more acceptor or donor groups, or a heteroaromatic ring having one or more heteroatoms, which may or may not be substituted by acceptor or donor groups.
R2 is a hydrogen atom, halogen atom, a C1-C5 alkyl radical, an oxygen atom that may or may not be substituted by a C1-C5 alkyl radical, or an NR5R5, radical where R5 and R5, are, independently of each other, a hydrogen atom, an oxygen atom or monovalent C1-C5 organic radicals.
这项发明涉及三环盐的治疗用途及其具有一般式的药用盐:其中:A可以是硫原子、氧原子或R3N基团,其中R3是氢原子、C1-C5烷基基团、或取代或未取代的芳香环,或取代或未取代的杂芳环。R1可以是C1-C5烷基基团,或R4NH基团,其中R4是氢原子、C1-C5烷基基团、或取代或未取代的芳香环,或取代或未取代的杂芳环,或者一种或多种受体或给体基团可能取代或未取代的芳香环,或具有一个或多个杂原子的杂芳环,该杂芳环可能取代或未取代受体或给体基团。R2是氢原子、卤素原子、C1-C5烷基基团、可能取代或未取代C1-C5烷基基团的氧原子,或NR5R5基团,其中R5和R5独立地是氢原子、氧原子或一价C1-C5有机基团。